“One study estimated that from 0.5 to five percent of all CTCLs occur in children,” as reported by National Organization of Rare Disorders. Causing the skin to develop small, pimple-looking lumps that can be felt or open sores, red patches, CTCL could even result in life-threatening complications.
MedC Biopharma Ltd., a Canadian manufacturer of cannabis-based medicines, is developing a cannabis centric solution for this very problem.
Founded in 2016 by Avi Drori, president and chairperson, and Guy Drori, CEO, MedC Biopharma Ltd.’s products are focused on post-traumatic stress disorder (PTSD), psoriasis and CTCL. The company has also signed an exclusive licensing agreement with National Medical Cannabis Research Lab at Agricultural Research Organization (ARO)—the Volcani Center, Israel.
“MedC Biopharma is developing a therapy on a full licensing track for a new drug, together with the approach that asserts that a combination of active ingredients from the plant produces a better response than a single active ingredient (the entourage effect),” as reported by the Israel business news outlet, Globes.